Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT

Current Pharmaceutical Design

Volumn 19, Issue 25, 2013, Pages 4647-4672

  Matusiak, Nathalie ^a   van Waarde, Aren ^a   Bischoff, Rainer ^b   Oltenfreiter, Ruth ^c   van de Wiele, Christophe ^c   Dierckx, Rudi A J O ^a,c   Elsinga, Philip H ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hydroxamates; MMP inhibitors; MMP peptides; Molecular imaging; PET; SPECT

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 10; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 5; COLLAGEN TYPE 7; COLLAGENASE 3; GELATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; KALININ; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 21; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE 26; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; UNCLASSIFIED DRUG;

ANEURYSM; ARTICLE; BONE REMODELING; CELL TRANSFORMATION; DISEASE ACTIVITY; DISULFIDE BOND; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; ISOTOPE LABELING; LIPID DIET; NIDATION; NONHUMAN; ORGANOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION; UPREGULATION; ZYMOGRAPHY;

ANIMALS; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR IMAGING; MOLECULAR PROBES; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84880379236     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319250011     Document Type: Article

References (83)

1. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes & Development 2003; 17(1): 7-30.
2. Hooper NM. Families of zinc metalloproteases. FEBS Letters 1994; 354: 0-5.
3. Stöcker W, Bode W. Structural features of a superfamily of zincendopeptidases: the metzincins. Curr Opinion in Structural Biol 1995; 5: 383-90.
4. Nagase H, Woessner JF. Matrix metalloproteinases. J Biological Chemistry 1999; 274(31): 21491-4.
5. Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol. 2002; 22(1): 51-86.
6. White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opinion Cell Biol 2003; 15(5): 598-606.
7. MacFadyen RJ. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine? Curr Opinion Pharmacol 2007; 7(2): 171-8.
8. Browner MF, Smith WW, Castelhano AL. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995; 34(20): 6602-10.
9. Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 2008; 27(4): 679-90.
10. Hu J, Van den Steen PE, Sang Q-X A, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discovery 2007; 6(6): 480-98.
11. Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chemical Rev 1999; 99(9): 2735-76.
12. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Institute 2001; 93(3): 178-93.
13. Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG. Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol 2008; 40(6-7): 1156-68.
14. Bremer C, Bredow S, Mahmood U, et al. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001; 221(2): 523-9.
15. Hutton M, Willenbrock F, Brocklehurst K, Murphy G. Kinetic analysis of the mechanism of interaction of full-length TIMP-2 and gelatinase A: evidence for the existence of a low-affinity intermediate. Biochemistry 1998; 37(28): 10094-8.
16. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995; 248: 496-511.
17. Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorganic Med Chem 2007; 15(6): 2223-68.
18. Sheppeck JE, Gilmore JL, Tebben A, et al. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorganic Med Chem Letters 2007; 17(10): 2769-74.
19. Stocker W, Bode W. Structural features of a superfamily of zincendopeptidases: the metzincins. Curr Opinion Structural Biol 1995; 5: 383-390.
20. Tung CH, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res 2000; 60(17): 4953-8.
21. Williamson RA, Marston FA, Angal S, et al. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J 1990; 268(2): 267-74.
22. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30(33): 8097-102.
23. Yang SW, Chanda D, Cody JJ, et al. Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. PloS One 2011; 6(10): e25131.
24. Giersing BK, Rae MT, CarballidoBrea M, Williamson RA, Blower PJ. Synthesis and characterization of 111In-DTPA-N-TIMP-2: a radiopharmaceutical for imaging matrix metalloproteinase expression. Bioconjugate Chemistry 2001; 12(6): 964-71.
25. Kulasegaram R, Giersing B, Page CJ, et al. In vivo evaluation of 111 In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. European J Nuclear Med Mol Imaging 2001; 28(6): 756-761.
26. Oltenfreiter R, Burvenich I, Staelens L, et al. Synthesis, quality control and in vivo evaluation of [123I] rhTIMP-2, a potential tumour-imaging agent. J Labelled Compounds Radiopharm 2005; 48(5): 387-396.
27. Van Steenkiste M, Oltenfreiter R, Frankenne F, et al. Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent. Cancer Biotherapy Radiopharm 2010; 25(5): 511-20.
28. Codd R. Traversing the coordination chemistry and chemical biology of hydroxamic acids. Coordination Chemistry Rev 2008; 252(12-14): 1387-1408.
29. Su H, Spinale FG, Dobrucki LW, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005; 112(20): 3157-67.
30. Zhang J, Nie L, Razavian M, et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 2008; 118(19): 1953-60.
31. Tavakoli S, Razavian M, Zhang J, et al. Matrix metalloproteinase activation predicts amelioration of remodeling after dietary modification in injured arteries. Arteriosclerosis, Thrombosis, Vascular Biol 2011; 31(1): 102-9.
32. Sahul ZH, Mukherjee R, Song J, et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circulation. Cardiovascular Imaging 2011; 4(4): 381-91.
33. Fujimoto S, Hartung D, Ohshima S, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am College Cardiol 2008; 52(23): 1847-57.
34. Ohshima S, Petrov A, Fujimoto S, et al. Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein E or low-density-lipoprotein receptor. J Nuclear Med 2009; 50(4): 612-7.
35. Ohshima S, Fujimoto S, Petrov A, et al. Effect of an antimicrobial agent on atherosclerotic plaques: assessment of metalloproteinase activity by molecular imaging. J Am College Cardiol 2010; 55(12): 1240-9.
36. Razavian M, Tavakoli S, Zhang J, et al. Atherosclerosis Plaque Heterogeneity and Response to Therapy Detected by In vivo Molecular Imaging of Matrix Metalloproteinase Activation. J Nuclear Med 2011; 52: 1795-1802.
37. Haider N, Hartung D, Fujimoto S, et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nuclear Cardiol 2009; 16(5): 753-62.
38. Tekabe Y, Li Q, Luma J, et al. Noninvasive monitoring the biology of atherosclerotic plaque development with radiolabeled annexin V and matrix metalloproteinase inhibitor in spontaneous atherosclerotic mice. J Nuclear Cardiol 2010; 17(6): 1073-81.
39. Razavian M, Zhang J, Nie L, et al. Molecular imaging of matrix metalloproteinase activation to predict murine aneurysm expansion in vivo. J Nuclear Med 2010; 51(7): 1107-15.
40. Bellac CL, Li Y, Lou Y, et al. Novel MMP inhibitor [18F]-Marimastat-aryltrifluoroborate as a probe for in vivo PET imaging in cancer. Cancer Res 2010; 70(19): 7562-9.
41. Li Y, Ting R, Harwig CW, et al. Towards kit-like 18F-labeling of marimastat, a noncovalent inhibitor drug for in vivo PET imaging cancer associated matrix metalloproteases. MedChemComm 2011; 2(10): 925-1022.
42. Oltenfreiter R, Staelens L, Lejeune A, et al. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Nuclear Med Biology 2004; 31(4): 459-68.
43. Oltenfreiter R, Staelens L, Labied S, et al. Tryptophane-Based Biphenylsulfonamide Matrix Metalloproteinase Inhibitors as Tumor Imaging Agents. Cancer Biotherapy Radiopharm 2005; 20(6): 639-48.
44. Oltenfreiter R, Staelens L, Kersemans V, et al. Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents. Applied Radiation Isotopes 2006; 64(6): 677-85.
45. Oltenfreiter R, Staelens L, Hillaert U, et al. Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents. Applied Radiation Isotopes 2005; 62(6): 903-13.
46. Fei X, Zheng Q-H, Liu X, et al. Synthesis of MMP inhibitor radiotracer [11C]CGS 25966, a new potential pet tumor imaging agent. J Labelled Compounds and Radiopharm 2003; 46(4): 343-51.
47. Zheng Q-H, Fei X, Liu X, et al. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[(4-[11C]methoxyphenyl)sulfonyl]benzyl amino]-3-methylbutanamide. Nuclear Med Biol 2004; 31(1): 77-85.
48. Fei X, Zheng Q-H, Hutchins GD, et al. Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents. J Labelled Compounds Radiopharm 2002; 45(6): 449-70.
49. MacPherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997; 40(16): 2525-32.
50. Wagner S, Law MP, Faust A, Ho C, Schro S. Novel Fluorinated Derivatives of the Broad-Spectrum MMP Inhibitors N-Hydroxy-2(R)-[(4-methoxyphenyl)sulfonyl](benzyl)-and (3-picolyl)-amino]-3-methyl-butanamide as Potential Tools for the Molecular Imaging of Activated MMPs with PET. J Med Chem 2007; 2: 5752-64.
51. Breyholz HJ, Wagner S, Levkau B, Schober O, Kopka K. A [18F]-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo Q. J Nucl Med Mol Imaging 2007; 51: 24-32
52. Wagner S, Faust A, Breyholz H-J, Schober O, Schäfers M, Kopka K. The MMP inhibitor (R)-2-(N-benzyl-4-(2-[18F]fluoroethoxy) phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis. Applied Radiation Isotopes 2011; 69(6): 862-8.
53. Zheng Q-H, Fei X, Liu X, et al. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nuclear Med Biol 2002; 29(7): 761-70.
54. Kopka K, Wagner S, Law MP, et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nuclear Med Biol 2004; 31: 257-267.
55. Schäfers M, Riemann B, Kopka K, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004; 109(21): 2554-9.
56. Kopka K, Schober O, Wagner S. (18)F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases. Basic Res Cardiology 2008; 103(2): 131-43.
57. Wagner S, Breyholz H-J, Höltke C, et al. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies. Applied Radiation Isotopes 2009; 67(4): 606-10.
58. Hugenberg V, Breyholz H-J, Riemann B, et al. A new class of highly potent matrix metalloproteinase inhibitors based on triazolesubstituted hydroxamates: (Radio)synthesis, in vitro and first in vivo evaluation. J Med Chem 2012; 55(10): 4714-27.
59. Fei X, Zheng Q-H, Liu X, et al. Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorganic Med Chem Lett 2003; 13(13): 2217-22.
60. Kuhnast B, Bodenstein C, Wester HJ, Weber W. Carbon-11 labelling of an N-sulfonylamino acid derivative: a potential tracer for MMP-2 and MMP-9 imaging. J Labelled Compounds Radiopharm 2003; 46(6): 539-53.
61. Furumoto S, Takashima K, Kubota K, Ido T, Iwata R, Fukuda H. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nuclear Med Biol 2003; 30(2): 119-25.
62. Furumoto S, Iwata R, Ido T. Design and synthesis of fluorine-18 labeled matrix metalloproteinase inhibitors for cancer imaging. J Labelled Compounds Radiopharm 2002; 45(11): 975-86.
63. Zheng Q-H, Fei X, DeGrado TR, et al. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester. Nuclear Med Biol 2003; 30(7): 753-60.
64. Sheppeck JE, Gilmore JL, Tebben A, et al. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorganic Med Chem Letters 2007; 17(10): 2769-74.
65. Breyholz H-J, Schäfers M, Wagner S, et al. C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. J Med Chem 2005; 48(9): 3400-9.
66. Breyholz H-J, Wagner S, Faust A, et al. Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging. ChemMedChem 2010; 5(5): 777-89.
67. Schrigten D, Breyholz H-J, Wagner S, et al. A New Generation of Radiofluorinated Pyrimidine-2,4,6-triones as MMP-Targeted Radiotracers for Positron Emission Tomography. J Med Chem 2012; 55(1): 223-32.
68. Claesener M, Schober O, Wagner S, Kopka K. Radiosynthesis of a 68Ga labeled matrix metalloproteinase inhibitor as a potential probe for PET imaging. Applied Radiation Isotopes 2012; 70(8): 1723-28.
69. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnology 1999; 17(8): 768-74.
70. Kuhnast B, Bodenstein C, Haubner R, et al. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nuclear Med Biol 2004; 31(3): 337-44.
71. Sprague JE, Li WP, Liang K, Achilefu S, Anderson CJ. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nuclear Med Biol 2006; 33(2): 227-37.
72. Hanaoka H, Mukai T, Habashita S, et al. Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors. Nuclear Med Biol 2007; 34(5): 503-10.
73. Ujula T, Huttunen M, Luoto P, et al. Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model. Bioconjugate Chem 2010; 21(9): 1612-21.
74. Cheng TL, Chuang CH, Chuang KH, et al. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a non-inhibitory protease substrate. Clinical Cancer Res 2012; 18(1): 238-47.
75. Huang CW, Li Z, Conti PS. Radioactive smart probe for potential corrected matrix metalloproteinase imaging. Bioconjugate Chem 2012; 23(11): 2159-67.
76. Murphy, G. Tissue inhibitors of metalloproteinases. Genome Biol 2011; 12(233): 1-7.
77. Agrawal A, Romero-Perez D, Jacobsen JA, Villarreal FJ, Cohen SM. Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 2008; 3(5): 812-20.
78. Sheppeck JE, Gilmore JL, Tebben A, et al. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorganic Med Chem Letters 2007; 17(10): 2769-74.
79. Pfaffen S, Frey K, Stutz I, Roesli C, Neri D. Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3. Eur J Nuclear Med and Molecular Imaging 2010; 37(8): 1559-65.
80. Temma T, Sano K, Kuge Y, et al. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors. Biological Pharmaceutical Bulletin 2009; 32(7): 1272-7.
81. Kuge Y, Takai N, Ogawa Y, et al. Imaging with radiolabelled antimembrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques. Eur J Nuclear Med Mol Imaging 2010; 37(11): 2093-104.
82. Watkins G, Jones EF, Scott Shell M, et al. Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorganic Med Chem 2009; 17(2): 653-9.
83. van Duijnhoven SMJ, Robillard MS, Nicolay K, Grüll H. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nuclear Med 2011; 52(2): 279-86.